Mavyret™ (glecaprevir/pibrentasvir) – New drug approval
August 3, 2017 – The FDA announced the approval of AbbVie’s Mavyret (glecaprevir/pibrentasvir), for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Top